• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Passively transferred M2e-specific monoclonal antibody reduces influenza A virus transmission in mice

tetano

Editor, Senior Moderator
Antiviral Res. 2018 Sep 1. pii: S0166-3542(18)30314-0. doi: 10.1016/j.antiviral.2018.08.017. [Epub ahead of print]
[h=1]Passively transferred M2e-specific monoclonal antibody reduces influenza A virus transmission in mice.[/h] Kolpe A[SUP]1[/SUP], Schepens B[SUP]1[/SUP], Ye L[SUP]2[/SUP], Staeheli P[SUP]3[/SUP], Saelens X[SUP]4[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Influenza represents a global public health threat. Currently available influenza vaccines are effective against strain-matched influenza A and B viruses but do not protect against novel pandemic viruses. Vaccine candidates that target conserved B or T cell epitopes of influenza viruses could circumvent this shortcoming. The conserved extracellular domain of matrix protein 2 (M2e) of influenza A is an example of such a broadly protective vaccine candidate. Protection by M2e-based vaccine candidates largely depends on M2e-specific IgG antibodies. Here we show that the M2e-specific IgG2a monoclonal antibody 65 (MAb 65) can reduce influenza A/Udorn/72 (H3N2) and A/Hong Kong/68 (H3N2) virus plaque formation. This effect was not observed with other influenza A virus strains tested. We further show that passive transfer of MAb 65 to mice can reduce viral loads in the upper and lower airways, which results in reduced transmission of A/Udorn/72 and A/Hong Kong/68 viruses to cohoused, unimmunized contact mice. Virus restriction by passively transferred Mab 65 was significantly less pronounced in Fcgr1[SUP]-/-[/SUP]Fcgr3[SUP]-/-[/SUP] mutant mice compared with wild type controls, suggesting that in vivo protection provided by MAb 65 depends on Fcγ receptor-mediated antibody effector mechanisms. We conclude that M2e-based antibody immune therapy has the potential to diminish influenza A virus replication in the immunized host as well as in exposed na?ve contacts.


[h=4]KEYWORDS:[/h] Broadly protecting antibody; Influenza A virus; M2 ectodomain; Mouse transmission model

PMID: 30179634 DOI: 10.1016/j.antiviral.2018.08.017
 
Back
Top Bottom